STAT Plus: Color me skeptical: Drinking gold is not an ALS cure
Adam’s Biotech Scorecard
Adam’s Biotech Scorecard is a subscriber-only newsletter offering unfiltered analysis from Adam Feuerstein, a veteran reporter with decades of experience covering the intersection of Wall Street and biotechnology. It’s delivered on Thursday mornings, and STAT+ subscribers can sign up here.
Latest
STAT Plus: What does Akeso’s primo plenary spot say about its survival data?
STAT Plus: Can Erasca be biotech’s next big thing? We’ll see
STAT Plus: Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway
STAT Plus: ‘Takeover Tuesday’ saves biotech’s quarter
STAT Plus: Allogene’s off-the-shelf CAR-T is nearing an early but pivotal study readout
STAT Plus: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era
STAT Plus: The extremism of the FDA’s Marks and Prasad has come with costs
All Coverage
